Thomas Albini, MD, discusses the outcomes of the MUST trial—a 2-year, prospective study that evaluates visual acuity outcomes in patients implanted with RETISERT®. Dr. Albini comments on the outcomes and safety findings of RETISERT® when compared with standard systemic therapy in patients with chronic noninfectious uveitis.
RETISERT® (ﬂuocinolone acetonide intravitreal implant) 0.59 mg is a corticosteroid indicated for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye.
Click here for full prescribing information on RETISERT®
®/™ are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other products/brand names are trademarks of the respective owners.
©Bausch & Lomb Incorporated. All rights reserved. RET.0036.USA.17